AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Resmed DRC

38.000

+0.3300.88%

Volume:740.31K

Turnover:28.18M

Market Cap:55.72B

PE:29.51

High:38.320

Open:38.000

Low:37.990

Close:37.670

Loading ...

Overview Company News Filings

ResMed’s Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep

ResMed Inc. Stock Rises Tuesday, Outperforms Market

HSIC Q4 Earnings Match Estimates, Margins Up, Stock Falls in Premarket

HIMS Stock Declines Following Q4 Earnings Miss, Gross Margin Contracts

Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat

ILMN Stock Might Rise From Collaboration With Broad Clinical Labs

ResMed Inc. (NYSE:RMD) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Simply Wall St.

Top Australian shares to buy right away with $2,000

AMN Stock Gains Following Q4 Earnings & Revenues Beat, Margins Down

ITGR Stock Declines Following Q4 Earnings Miss, Gross Margin Contract

PODD Stock Falls Despite Q4 Earnings and Revenue Beat, Margins Rise

Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips

CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall

Insulet Earnings: What To Look For From PODD

iRhythm (IRTC) To Report Earnings Tomorrow: Here Is What To Expect

ResMed Inc. Stock Falls Tuesday, Underperforms Market

Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles

BIO Stock Might Rise Following the Offer to Acquire Stilla

BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket

PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments Fall

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RMD.AU/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RMD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RMD.AU\",,,,,undefined,":{"symbol":"RMD.AU","market":"AU","secType":"STK","nameCN":"Resmed DRC","latestPrice":38,"timestamp":1746684720000,"preClose":37.67,"halted":0,"volume":740310,"delay":0,"nameEN":"Resmed DRC","floatShares":145691036,"shares":1466188140,"eps":1.2877144239624143,"marketStatus":"Not Yet Opened","change":0.33,"latestTime":"05-08 16:12:00 AEST","open":38,"high":38.32,"low":37.99,"amount":28177864,"amplitude":0.00876,"askPrice":38.25,"askSize":373,"bidPrice":37.8,"bidSize":51,"shortable":3,"etf":0,"ttmEps":1.2877144239624143,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746748800000},"marketStatusCode":0,"adr":0,"adrRate":1,"exchange":"ASX","adjPreClose":37.67,"dividendRate":0.008035,"openAndCloseTimeList":[[1746662400000,1746684000000]],"volumeRatio":1.063257,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RMD.AU\",,,,,undefined,":{"symbol":"RMD.AU","floatShares":145691036,"roa":"14.01%","roe":"25.81%","lyrEps":0.975541,"volumeRatio":1.063257,"shares":1466188140,"dividePrice":0.307491,"high":38.32,"amplitude":0.00876,"preClose":37.67,"low":37.99,"week52Low":26.887,"pbRate":"6.44","psRate":"7.11","week52High":40.571,"institutionHeld":0,"latestPrice":38,"committee":-0.759434,"eps":1.2877144239624143,"divideRate":0.008035,"volume":740310,"delay":0,"ttmEps":1.2877144239624143,"open":38,"prevYearClose":36.609,"prevWeekClose":37.178,"prevMonthClose":36.599,"prevQuarterClose":34.883,"fiveDayClose":36.819,"twentyDayClose":33.387,"sixtyDayClose":37.744},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RMD.AU\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514074530","title":"ResMed’s Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep","url":"https://stock-news.laohu8.com/highlight/detail?id=2514074530","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514074530?lang=en_us&edition=fundamental","pubTime":"2025-02-26 16:00","pubTimestamp":1740556800,"startTime":"0","endTime":"0","summary":"New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships. 7 out of 10 employed respondents have called in sick at least once in their career due to poor sleep.18% of couples reported sleeping in separate rooms due to snoring and restlessness.SAN DIEGO, Feb. 26, 2025  -- ResMed , a global health technology leader focused on sleep, breathing, and care delivered in the home, today unveiled the findings of its fifth annual Global Sleep Survey. With insights from 30,026 respondents across 13 markets, the study underscores a widespread global sleep crisis, with people losing an average of nearly three nights of restorative sleep each week.Despite a trend towards growing awareness of sleep’s importance, many continue to suffer in silence and remain trapped in a cycle of exhaustion. The research reveals that nearly one in four (22%) respondents choose to just live with poor sleep rather than seek help. With poor sle","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/resmed-fifth-annual-global-sleep-080000515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4504","BK4548","RMD","RMD.AU","BK4567","LU2177674079.SGD","BK4588","LU2008162690.USD","BK4585","BK4082"],"gpt_icon":1},{"id":"2514042209","title":"ResMed Inc. Stock Rises Tuesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2514042209","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514042209?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:57","pubTimestamp":1740520620,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of ResMed Inc.  rose 2.85% to $236.19 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average  rising 0.37% to 43,621.16 and the S&P 500 Index  falling 0.47% to 5,955.25.The stock's rise snapped a three-day losing streak.ResMed Inc. closed 10.21% short of its 52-week high of $263.05, which the company reached on January 30th.Trading volume  eclipsed its 50-day average volume of 924,102.Data source: Dow Jones Market Data, FactSet. Data compiled February 25, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD.AU","RMD"],"gpt_icon":0},{"id":"2514012244","title":"HSIC Q4 Earnings Match Estimates, Margins Up, Stock Falls in Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2514012244","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514012244?lang=en_us&edition=fundamental","pubTime":"2025-02-26 00:28","pubTimestamp":1740500880,"startTime":"0","endTime":"0","summary":"Henry Schein, Inc. HSIC registered adjusted earnings per share  of $1.19 in the fourth quarter of 2024, up 80.3% from the year-ago period’s EPS of 66 cents. The figure was in line with the Zacks Consensus Estimate.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The company reported GAAP EPS of 74 cents compared with the year-ago quarter’s 13 cents.Full-year 2024 EPS of $4.74 increased 5.3% from the prior-year level. The figure missed the Zacks Consensus Estimate by 0.2%.Following the earnings announcement, HSIC stock lost 1.4% at pre-market trading today.On a geographic basis, the company recorded sales of $1.86 billion in the United States, up 5.3% year over year.In the fourth quarter, the company recorded $2.70 billion in Global Distribution and Value-Added Services sales, up 5.9% year over year.During the reported quarter, HSIC repurchased nearly 1.1 million shares of its common stock at an average price of $71.35 per share for a total of approximately $75 mil","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hsic-q4-earnings-match-estimates-162800199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RMD.AU","BIO","HSIC","CAH","MTCH","RMD"],"gpt_icon":0},{"id":"2514012223","title":"HIMS Stock Declines Following Q4 Earnings Miss, Gross Margin Contracts","url":"https://stock-news.laohu8.com/highlight/detail?id=2514012223","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514012223?lang=en_us&edition=fundamental","pubTime":"2025-02-26 00:06","pubTimestamp":1740499560,"startTime":"0","endTime":"0","summary":"Hims & Hers Health, Inc. HIMS delivered an earnings per share  of 11 cents in fourth-quarter 2024, compared with the year-ago period’s EPS of a penny. However, the metric missed the Zacks Consensus Estimate by a penny.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Full-year 2024 EPS was 53 cents against the comparable year-ago period’s loss of 11 cents per share. However, the metric lagged the Zacks Consensus Estimate by 3.6%.Hims & Hers registered revenues of $481.1 million in the fourth quarter, up 95.1% year over year. The figure beat the Zacks Consensus Estimate by 2.1%.Solid revenues from both Online and Wholesale channels drove the top line.In the quarter under review, Online Revenues of $470.8 million reflected an increase of 98.3% year over year on a reported basis.During the reported quarter, subscribers were 2.2 million .Wholesale Revenues totaled $10.4 million, up 12.1% year over year.Hims & Hers Health, Inc. Price, Consensus and EPS Surprise. Hims & ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hims-stock-declines-following-q4-160600293.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HIMS","CAH","RMD","BSX","RMD.AU"],"gpt_icon":1},{"id":"2514097648","title":"Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2514097648","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514097648?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:00","pubTimestamp":1740488400,"startTime":"0","endTime":"0","summary":"Veracyte VCYT delivered fourth-quarter 2024 earnings of 36 cents per share, which marked a stupendous improvement of 71.4% from the year-ago period’s figure of 21 cents. The bottom line beat the Zacks Consensus Estimate by 24.1%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.The company-adjusted earnings per share  were 6 cents compared to the year-ago period’s loss of 39 cents per share.Full-year 2024 EPS of $1.19 increased 105.2% from the prior-year figure of 58 cents. The figure surpassed the Zacks Consensus Estimate by 6.2%.Following the earnings announcement, VCYT’s share price lost 7.2% at after-market trading yesterday.Revenues increased 20.8% year over year to $118.6 million, which outpaced the Zacks Consensus Estimate by 1.6%.The company reported full-year 2024 revenues of $445.8 million, which increased 23.5% from the prior-year level. The figure surpassed the Zacks Consensus Estimate by 0.4%.Testing revenues totaled $112.2 million, up 24% year over ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/veracyte-stock-falls-despite-q4-130000857.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BIO","VCYT","RMD.AU","RMD","CAH"],"gpt_icon":0},{"id":"2514752497","title":"ILMN Stock Might Rise From Collaboration With Broad Clinical Labs","url":"https://stock-news.laohu8.com/highlight/detail?id=2514752497","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514752497?lang=en_us&edition=fundamental","pubTime":"2025-02-24 23:12","pubTimestamp":1740409920,"startTime":"0","endTime":"0","summary":"Illumina, Inc. ILMN recently entered into a collaboration with Broad Clinical Labs to rapidly streamline and scale single-cell projects with cutting-edge tools and workflows. Together, the companies aim to accelerate the development of a 5-billion cell atlas within the next three years.Following the Feb. 21 announcement, Illumina’s shares lost 3.1% to close at $94.20 last Friday. The company has democratized sequencing over the past 20 years, and set the standard in whole genome sequencing. This partnership with Broad Clinical Labs should help researchers process and analyze unprecedented volumes of single-cell reads with unparalleled speed and accuracy to facilitate large-scale functional genomics studies and accelerate discovery in areas such as disease modeling and drug development. As a result, we anticipate this collaboration to boost market sentiment toward ILMN stock in the coming days.Illumina presently has a market capitalization of $14.92 billion. The Zacks Consensus Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ilmn-stock-might-rise-collaboration-151200575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RMD","NVDS","LU2491050071.SGD","LU0417517546.SGD","NVDD","LU2552382132.HKD","IE0004445015.USD","LU2106854487.HKD","OMCL","LU1429558221.USD","LU0820562030.AUD","SNVD.UK","LU2505996681.GBP","LU2491049909.HKD","NVDX","LU0061475181.USD","NVIW.SI","ILMN","VCYT","IE00BD6J9T35.USD","NVDS.UK","LU1323610961.USD","RMD.AU","3NVD.UK","NVD","LU0788109477.HKD","NVD3.UK","LU1145028129.USD","NVD2.UK","NVDY","LU1852331112.SGD","IE00BJTD4V19.USD","LU2361044949.HKD","LU0170899867.USD","LU0069063385.USD","IE00BK4W5M84.HKD","2NVD.UK","LU0964807845.USD","LU1923623000.USD","NVDU","LU1261432733.SGD","SGXZ23171101.USD","LU0345769128.USD","LU2083900584.USD","BK4585","IE00BK4W5L77.USD","LU2177674079.SGD","LU2294711713.HKD","LU0289961442.SGD"],"gpt_icon":1},{"id":"2513729535","title":"ResMed Inc. (NYSE:RMD) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?","url":"https://stock-news.laohu8.com/highlight/detail?id=2513729535","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513729535?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:00","pubTimestamp":1740402024,"startTime":"0","endTime":"0","summary":"ResMed  has had a rough month with its share price down 7.5%. However, stock prices are usually driven by a company’s financial performance over the long term, which in this case looks quite promising. In this article, we decided to focus on ResMed's  ROE.Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. Put another way, it reveals the company's success at turning shareholder investments into profits.Return on Equity = Net Profit  ÷ Shareholders' Equity. So, based on the above formula, the ROE for ResMed is:. Additionally, ResMed has paid dividends over a period of at least ten years which means that the company is pretty serious about sharing its profits with shareholders. Based on the latest","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/resmed-inc-nyse-rmd-stock-130024223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4504","BK4548","BK4585","BK4588","LU2008162690.USD","NYSE","RMD.AU","LU2177674079.SGD","BK4567","BK7501","RMD","BK4082","BK7007"],"gpt_icon":1},{"id":"2513650203","title":"Top Australian shares to buy right away with $2,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2513650203","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513650203?lang=en_us&edition=fundamental","pubTime":"2025-02-23 00:30","pubTimestamp":1740241800,"startTime":"0","endTime":"0","summary":"Do you have $2,000 to invest into the share market?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/23/top-australian-shares-to-buy-right-away-with-2000-2/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4504","LU1668664300.SGD","LU1868836914.USD","LU2471134879.HKD","XAO.AU","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LU2237438978.USD","LU0061475181.USD","LU2237443549.SGD","XKO.AU","BK4585","LU1868836591.USD","BK4588","LU2471134523.USD","IE00BFXG1179.USD","LU2471134952.CNY","LU2237443978.SGD","IE0004091025.USD","LU1868836757.USD","LU2471134796.USD","LU2237443895.HKD","BK7501","IE0004086264.USD","LU1868837136.USD","BK4552","BK7016","IE0034235188.USD","LU2750360997.AUD","XJO.AU","BK4533","LU0096364046.USD","LU0106831901.USD","BK7007","LU2237443382.USD","LU2237443465.HKD","IE00B19Z3581.USD","LU2237443622.USD","IE0002270589.USD","RMD.AU","BK4127","LU1868837300.USD","BK4516","WTC.AU","BK4550","BK7503","LU2750360641.GBP","LU1791807156.HKD"],"gpt_icon":0},{"id":"2513218653","title":"AMN Stock Gains Following Q4 Earnings & Revenues Beat, Margins Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2513218653","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513218653?lang=en_us&edition=fundamental","pubTime":"2025-02-21 23:39","pubTimestamp":1740152340,"startTime":"0","endTime":"0","summary":"AMN Healthcare Services, Inc. AMN delivered adjusted earnings per share  of 75 cents in the fourth quarter of 2024, which declined 43.2% year over year. However, the figure surpassed the Zacks Consensus Estimate by 44.2%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.GAAP loss per share for the quarter was $4.90 against EPS of 33 cents in the year-ago period.Full-year 2024 EPS was $3.31, down 59.7% from the comparable 2023 period. However, the metric surpassed the Zacks Consensus Estimate by 7.8%.AMN Healthcare registered revenues of $734.7 million in the fourth quarter, down 10.2% year over year. However, the figure surpassed the Zacks Consensus Estimate by 5.7%.AMN Healthcare conducts its business via three reportable segments — Nurse and Allied Solutions, Physician and Leadership Solutions and Technology and Workforce Solutions.AMN Healthcare Services Inc Price, Consensus and EPS Surprise. AMN Healthcare Services Inc price-consensus-eps-surprise-chart | AMN H","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amn-stock-gains-following-q4-153900524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["AMN","RMD.AU","RMD","BSX","CAH"],"gpt_icon":0},{"id":"2513655218","title":"ITGR Stock Declines Following Q4 Earnings Miss, Gross Margin Contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2513655218","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513655218?lang=en_us&edition=fundamental","pubTime":"2025-02-21 23:38","pubTimestamp":1740152280,"startTime":"0","endTime":"0","summary":"Integer Holdings Corporation ITGR delivered adjusted earnings per share  of $1.43 in the fourth quarter of 2024, which improved 1.4% year over year. The figure missed the Zacks Consensus Estimate by 2.1%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The adjustments include expenses related to the amortization of intangible assets and restructuring and restructuring-related charges, among others.GAAP EPS for the quarter was 91 cents, reflecting an improvement of 15.2% year over year.Full-year 2024 EPS was $5.30, up 14.9% from the comparable 2023 period. However, the metric lagged the Zacks Consensus Estimate by 0.6%.Integer Holdings registered revenues of $449.5 million in the fourth quarter, up 11.1% year over year. The figure topped the Zacks Consensus Estimate by 0.8%.Integer Holdings operates through three product lines — Cardio and Vascular (C&V); Cardiac Rhythm Management & Neuromodulation  and Other Markets.Integer Holdings Corporation Price, Consensus an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/itgr-stock-declines-following-q4-153800417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RMD.AU","CAH","RMD","BSX","ITGR"],"gpt_icon":0},{"id":"2513291652","title":"PODD Stock Falls Despite Q4 Earnings and Revenue Beat, Margins Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2513291652","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513291652?lang=en_us&edition=fundamental","pubTime":"2025-02-21 21:39","pubTimestamp":1740145140,"startTime":"0","endTime":"0","summary":"Insulet Corporation PODD reported fourth-quarter 2024 adjusted earnings per share  of $1.15, down significantly 17.8% from the year-ago period’s figure. The bottom line surpassed the Zacks Consensus Estimate by 9.5%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.GAAP EPS was $1.39, down 3.5% from the year-ago figure of $1.44.Full-year 2024 EPS of $3.24 increased 17.8% from the prior-year level. The figure surpassed the Zacks Consensus Estimate by 0.6%.Following the earnings announcement, PODD’s share price lost 3.6% at after-market trading yesterday.Revenues totaled $597.5 million, which beat the Zacks Consensus Estimate by 2.7%. The top line jumped 17.2% year over year and 17.1% at constant exchange rate or CER. CER growth exceeded the company’s guidance of 12-15%.The company reported full-year 2024 revenues of $2.10 billion, which increased 22.1% from the prior-year level. The figure surpassed the Zacks Consensus Estimate by 1.9%.The operating profit in the qu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/podd-stock-falls-despite-q4-133900678.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["CAH","DGX","PODD","RMD","RMD.AU"],"gpt_icon":0},{"id":"2513916572","title":"Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips","url":"https://stock-news.laohu8.com/highlight/detail?id=2513916572","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513916572?lang=en_us&edition=fundamental","pubTime":"2025-02-21 21:17","pubTimestamp":1740143820,"startTime":"0","endTime":"0","summary":"Globus Medical, Inc. GMED reported fourth-quarter 2024adjusted earnings per share  of 84 cents, which beat the Zacks Consensus Estimate by 10.5%. The figure increased 40% year over year.Find the latest EPS estimates and surprises on ZacksEarnings Calendar.The adjusted EPS excludes certain non-recurring expenses and benefits, such as the amortization of intangibles, merger and acquisition-related costs/licensing and provision for litigation.Without adjustments, the company registered a GAAP diluted EPS of 19 cents, up 72.7% from the year-ago period’s figure.For the full year, adjusted earnings were $3.04 per share, 31% up from the year-ago period. The metric also surpassed the Zacks Consensus Estimate by 2%.Worldwide sales increased 6.6% year over year to $657.3 million. The reported figure exceeded the Zacks Consensus Estimate by 2%.Net sales improvement was driven by the addition of NuVasive, as well as increased volume of spine product sales and enabling technology volume.Globus Medi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/globus-medical-q4-earnings-revenues-131700477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BIO","RMD","CAH","GMED","RMD.AU"],"gpt_icon":0},{"id":"2512312774","title":"CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2512312774","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512312774?lang=en_us&edition=fundamental","pubTime":"2025-02-20 02:51","pubTimestamp":1739991060,"startTime":"0","endTime":"0","summary":"Charles River Laboratories International, Inc. CRL reported fourth-quarter 2024 adjusted earnings per share  of $2.66, which rose 8.1% year over year. The figure surpassed the Zacks Consensus Estimate by 6.4%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.On a GAAP basis, the company reported a loss of $4.22 per share against the year-ago quarter’s earnings of $3.62 per share.The company reported full-year 2024 EPS of $10.32, which decreased 3.3% from the prior-year level. The figure, however, surpassed the Zacks Consensus Estimate by 1.6%.Following the earnings announcement, CRL stock rose 1% in pre-market trading today.RMS’ revenues in the fourth quarter totaled $204.3 million, up 4.3% year over year . The organic decline in revenues was primarily due to lower revenues from research model services and the Cell Solutions business, as well as lower sales from non-human primates  in China. This was partially offset by higher sales of small research models. Our ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crl-stock-q4-earnings-revenue-185100192.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RMD","RMD.AU","CAH","CRL","DGX"],"gpt_icon":1},{"id":"2512438144","title":"Insulet Earnings: What To Look For From PODD","url":"https://stock-news.laohu8.com/highlight/detail?id=2512438144","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512438144?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:11","pubTimestamp":1739970692,"startTime":"0","endTime":"0","summary":"Insulin delivery company Insulet Corporation  will be announcing earnings results tomorrow after market close. Here’s what to expect.Insulet beat analysts’ revenue expectations by 4.9% last quarter, reporting revenues of $543.9 million, up 25.7% year on year. It was a stunning quarter for the company, with an impressive beat of analysts’ constant currency revenue and EPS estimates.Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insulet-earnings-look-podd-131132487.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RMD.AU","PODD","RMD"],"gpt_icon":0},{"id":"2512480762","title":"iRhythm (IRTC) To Report Earnings Tomorrow: Here Is What To Expect","url":"https://stock-news.laohu8.com/highlight/detail?id=2512480762","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512480762?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:01","pubTimestamp":1739970086,"startTime":"0","endTime":"0","summary":"Medical technology company iRhythm Technologies  will be announcing earnings results tomorrow afternoon. Here’s what investors should know.iRhythm met analysts’ revenue expectations last quarter, reporting revenues of $147.5 million, up 18.4% year on year. It was a softer quarter for the company, with a significant miss of analysts’ EPS estimates.Is iRhythm a buy or sell going into earnings?Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/irhythm-irtc-report-earnings-tomorrow-130126025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RMD","RMD.AU","IRTC"],"gpt_icon":0},{"id":"2512911381","title":"ResMed Inc. Stock Falls Tuesday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2512911381","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512911381?lang=en_us&edition=fundamental","pubTime":"2025-02-19 05:57","pubTimestamp":1739915820,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of ResMed Inc.  slipped 1.03% to $230.58 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index  rising 0.24% to 6,129.58 and the Dow Jones Industrial Average  rising 0.02% to 44,556.34.This was the stock's second consecutive day of losses.ResMed Inc. closed 12.34% below its 52-week high of $263.05, which the company reached on January 30th.Trading volume  eclipsed its 50-day average volume of 888,005.Data source: Dow Jones Market Data, FactSet. Data compiled February 18, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD.AU","RMD"],"gpt_icon":1},{"id":"2512063169","title":"Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles","url":"https://stock-news.laohu8.com/highlight/detail?id=2512063169","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512063169?lang=en_us&edition=fundamental","pubTime":"2025-02-18 22:18","pubTimestamp":1739888280,"startTime":"0","endTime":"0","summary":"Medtronic plcMDT reported adjusted earnings per share  of $1.39 for the third quarter fiscal of 2025, up 6.9% from the year-ago quarter’s figure. The figure also beat the Zacks Consensus Estimate by 2.2%. Currency-adjusted EPS for the reported quarter was $1.38.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Without certain one-time adjustments — including amortization, restructuring and associated costs, certain litigation charges and acquisition-related costs, among others — GAAP EPS was $1.01, a 2% improvement from the year-ago quarter’s reported figure.Worldwide revenues in the reported quarter grossed $8.29 billion, up 2.5% year over year on a reported basis and 4.1% on an organic basis. The top line missed the Zacks Consensus Estimate by 0.4%.Following the announcement today, MDT shares dipped nearly 1.7% in the premarket trading.For the full fiscal 2025, Medtronic continues to project organic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medtronic-q3-earnings-top-estimates-141800403.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RMD.AU","MDT","RMD","BIO","CAH"],"gpt_icon":1},{"id":"2512353163","title":"BIO Stock Might Rise Following the Offer to Acquire Stilla","url":"https://stock-news.laohu8.com/highlight/detail?id=2512353163","media":"Zacks","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512353163?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:30","pubTimestamp":1739881800,"startTime":"0","endTime":"0","summary":"Bio-Rad Laboratories, Inc. BIO recently entered into a binding agreement to purchase all equity interests in Stilla Technologies . Stilla’s next-generation digital PCR solutions complement Bio-Rad’s digital PCR portfolio. The acquisition should further expand Bio-Rad’s business into applied research and clinical diagnostics, where customers expect a higher degree of automation and throughput capabilities.The acquisition is subject to consultation with relevant employee representatives, regulatory approvals and other customary closing conditions. The acquisition is expected to be closed by the end of the third quarter of 2025.Since the announcement, BIO stock has lost 9.5% to $277.16 last Friday.The company has been gaining synergies from its digital PCR platform’s increased penetration in advanced clinical diagnostic applications, both directly and through various partnerships. In 2024, Bio-Rad was involved in various collaborations, including an additional equity investment in OncoCyt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bio-stock-might-rise-following-123000827.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VCYT","BK4504","LU2177674079.SGD","BK4139","RMD","BK4082","BK4121","BIO","LU1169589451.USD","BK4585","LU1169590202.USD","LU2008162690.USD","BK4167","RMD.AU","BK4548","BK4567","OMCL","BK4588"],"gpt_icon":0},{"id":"2511661419","title":"BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2511661419","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511661419?lang=en_us&edition=fundamental","pubTime":"2025-02-15 02:57","pubTimestamp":1739559420,"startTime":"0","endTime":"0","summary":"Bio-Rad Laboratories, Inc. BIO posted fourth-quarter 2024 adjusted earnings per share  of $2.90, which missed the Zacks Consensus Estimate of $2.93 by 1.0%. The bottom line decreased 6.4% from the prior-year quarter’s level.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The quarter’s adjustments primarily eliminate the impacts of certain non-recurring items, such as the amortization of purchased intangibles, restructuring costs and losses from the change in the fair market value of equity securities.The company’s GAAP loss per share was $25.57 compared to the year-ago GAAP EPS of $12.14.The company reported full-year 2024 EPS of $10.31, which decreased 12.5% from the prior-year level. The figure missed the Zacks Consensus Estimate marginally by 0.2%.Following the earnings announcement, BIO stock declined 0.4% in yesterday’s after-market trading.The company reported full-year 2024 revenues of $2.57 billion, which decreased 3.9% from the prior-year level. The figu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bio-q4-earnings-revenues-miss-185700312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RMD.AU","CAH","DGX","RMD","BIO"],"gpt_icon":0},{"id":"2511761898","title":"PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2511761898","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511761898?lang=en_us&edition=fundamental","pubTime":"2025-02-15 00:04","pubTimestamp":1739549040,"startTime":"0","endTime":"0","summary":"Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, delivered an adjusted loss per share of 20 cents in fourth-quarter 2024, narrower than the year-ago adjusted loss of 27 cents per share. The adjusted loss per share was in line with the Zacks Consensus Estimate.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The company’s GAAP earnings per share  was a penny in the quarter against the year-ago period’s loss of 31 cents.Full-year adjusted loss per share was 83 cents, narrower than the adjusted loss of $1.11 per share at the end of the comparable 2023 period. However, the figure was wider than the Zacks Consensus Estimate of a loss of 81 cents.PacBio registered revenues of $39.2 million in the fourth quarter, down 32.8% year over year. However, the figure surpassed the Zacks Consensus Estimate by 0.1%.In the Asia-Pacific region, PacBio recorded revenues of $8.9 million, reflecting a 33% decline year over year. The sequential growth in consumab","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pacb-stock-down-following-line-160400123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["PACB","RMD.AU","RMD","BSX","CAH"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RMD.AU\",params:#limit:5,,,undefined,":[{"date":"2025-05-07","symbol":"RMD.AU","amount":0.053,"announcedDate":"2025-04-24","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-05-08","defaultRemindTime":1746576000000,"name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-12","payableDate":"2025-05-08","currency":"USD","dateTimestamp":1746540000000,"payDate":"2025-06-12"},{"date":"2025-02-12","symbol":"RMD.AU","amount":0.053,"announcedDate":"2025-01-31","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-02-13","name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-20","payableDate":"2025-02-13","currency":"USD","dateTimestamp":1739278800000,"payDate":"2025-03-20"},{"date":"2024-11-06","symbol":"RMD.AU","amount":0.053,"announcedDate":"2024-10-25","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-11-07","name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-12","payableDate":"2024-11-07","currency":"USD","dateTimestamp":1730811600000,"payDate":"2024-12-12"},{"date":"2024-08-14","symbol":"RMD.AU","amount":0.053,"announcedDate":"2024-08-02","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-08-15","defaultRemindTime":1723593600000,"name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-19","payableDate":"2024-08-15","currency":"USD","dateTimestamp":1723557600000,"payDate":"2024-09-19"},{"date":"2024-05-08","symbol":"RMD.AU","amount":0.048,"announcedDate":"2024-04-26","type":"dividend","market":"AU","newRecordDate":"2024-05-09","defaultRemindTime":1715126400000,"name":"Resmed DRC","recordDate":"2024-06-13","payableDate":"2024-05-09","currency":"USD","dateTimestamp":1715090400000,"payDate":"2024-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RMD.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-08-19","recordDate":"2020-08-20","paymentDate":"2020-09-24","value":0.039,"currency":"USD"},{"executeDate":"2020-11-11","recordDate":"2020-11-12","paymentDate":"2020-12-17","value":0.039,"currency":"USD"},{"executeDate":"2021-02-10","recordDate":"2021-02-11","paymentDate":"2021-03-18","value":0.039,"currency":"USD"},{"executeDate":"2021-05-12","recordDate":"2021-05-13","paymentDate":"2021-06-17","value":0.039,"currency":"USD"},{"executeDate":"2021-08-18","recordDate":"2021-08-19","paymentDate":"2021-09-23","value":0.042,"currency":"USD"}]}}